Medics Autonomously Stopping Hemorrhage (MASH)
SOL #: DARPA-PS-25-34Solicitation
Overview
Buyer
DEPT OF DEFENSE
Defense Advanced Research Projects Agency (Darpa)
DEF ADVANCED RESEARCH PROJECTS AGCY
ARLINGTON, VA, 222032114, United States
Place of Performance
Place of performance not available
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
PSC
National Defense R&D Services; Department Of Defense Military; Applied Research (AC12)
Set Aside
No set aside specified
Original Source
Timeline
1
Posted
Sep 16, 2025
2
Last Updated
Oct 8, 2025
3
Submission Deadline
Nov 25, 2025, 4:00 PM
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
The purpose of Amendment 1 to DARPA-PS-25-34, the Medics Autonomously Stopping Hemorrhage (MASH) Program Solicitation (PS), is to clarify that proposal abstract submissions must include Attachments A-C. Details are provided in Attachment A, to mirror guidance provided in Section 4.1 of DARPA-PS-25-34.
The Defense Advanced Research Projects Agency (DARPA) is soliciting proposals to develop demonstrator autonomous systems to stabilize torso hemorrhage without need of a surgeon in forward medical sites, providing 48+ hours to reach definitive care. The Medics Autonomously Stopping Hemorrhage (MASH) program is seeking approaches that merge multi-modal automated bleed detection and localization with automated, minimally invasive robotic end effectors and sensors. MASH’s vision is to push the standard of pre-hospital hemorrhage control to 48 hours; stop lethal forms of torso hemorrhage without a surgeon; and provide minimally invasive surgery (MIS) a path to enter the trauma market and utilize full autonomy.
The Defense Advanced Research Projects Agency (DARPA) is soliciting proposals to develop demonstrator autonomous systems to stabilize torso hemorrhage without need of a surgeon in forward medical sites, providing 48+ hours to reach definitive care. The Medics Autonomously Stopping Hemorrhage (MASH) program is seeking approaches that merge multi-modal automated bleed detection and localization with automated, minimally invasive robotic end effectors and sensors. MASH’s vision is to push the standard of pre-hospital hemorrhage control to 48 hours; stop lethal forms of torso hemorrhage without a surgeon; and provide minimally invasive surgery (MIS) a path to enter the trauma market and utilize full autonomy.
People
Points of Contact
BAA CoordinatorPRIMARY
Files
Versions
Version 2Viewing
Solicitation
Posted: Oct 8, 2025
Version 1
Solicitation
Posted: Sep 16, 2025